Advanced Solid Tumors and Advanced Malignancies
Pharma Mar S.A. focuses on advanced solid tumors and broader advanced malignancies, with studies spanning heavily pretreated adult patients and multiple tumor types. Its clinical program includes interest in selected advanced solid tumors and basket-style oncology development across refractory disease settings.
- Selected advanced solid tumors
- Advanced malignancies
- Pretreated oncology populations
These oncology trials reflect sustained activity in difficult-to-treat solid tumor settings across multiple collaborating sites and countries.
Small Cell Lung Cancer
The sponsor has a clear therapeutic interest in small cell lung cancer, particularly in the relapsed setting after prior platinum-based treatment. Trial activity in this area includes comparative evaluation of treatment options for patients with recurrent disease.
- Relapsed small cell lung cancer
- Post-platinum treatment setting
- Survival-focused oncology endpoints
This area highlights a dedicated oncology portfolio addressing aggressive lung cancer with limited treatment options.
Metastatic Leiomyosarcoma
Pharma Mar S.A. is also active in metastatic leiomyosarcoma, a rare and challenging soft tissue sarcoma. The clinical work in this domain centers on first-line treatment strategies for patients with advanced disease.
- Metastatic leiomyosarcoma
- Soft tissue sarcoma
- First-line advanced cancer treatment
This therapeutic focus extends the sponsor’s oncology research beyond common solid tumors into rarer malignant conditions.
Combination Oncology and Immunotherapy
Another major area of interest is the use of combination oncology approaches, including studies pairing anticancer agents with immunotherapy such as pembrolizumab and atezolizumab. The sponsor’s research also includes combinations with established cytotoxic agents in advanced cancer populations.
- Immunotherapy combinations
- Checkpoint inhibitor-based regimens
- Advanced solid tumor combinations
This area shows an emphasis on treatment strategies designed for patients with refractory or progressive disease.
Viral Diseases
Beyond oncology, Pharma Mar S.A. has research activity in viral diseases, indicating interest in infectious disease therapeutics alongside its cancer portfolio.
- Viral diseases
- Non-oncology therapeutic development
This adds a distinct infectious disease dimension to the sponsor’s clinical research landscape.
